MIRA Pharmaceuticals (NASDAQ:MIRA) and Annovis Bio (NYSE:ANVS) Critical Analysis

MIRA Pharmaceuticals (NASDAQ:MIRA) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares MIRA Pharmaceuticals and Annovis Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-236.29%	-213.97%
Annovis Bio	N/A	-153.50%	-125.51%

Earnings and Valuation

This table compares MIRA Pharmaceuticals and Annovis Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$7.85 million	($1.53)	-0.96
Annovis Bio	N/A	N/A	-$24.59 million	($1.44)	-3.41

Annovis Bio is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for MIRA Pharmaceuticals and Annovis Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1	0	0	0	1.00
Annovis Bio	1	2	2	0	2.20

Annovis Bio has a consensus target price of $13.50, suggesting a potential upside of 175.06%. Given Annovis Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Annovis Bio is more favorable than MIRA Pharmaceuticals.

Insider and Institutional Ownership

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

MIRA Pharmaceuticals has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.

Summary

Annovis Bio beats MIRA Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.